Long-term safety of facilitated subcutaneous immunoglobulin: Insights from a postauthorization safety study in primary immunodeficiency diseases (PID)

被引：0

作者：

Rubinstein, Arye ^{[1
,2
]}

Patel, Niraj C. ^{[3
]}

Wedner, H. James ^{[4
]}

Wasserman, Richard L. ^{[5
]}

Gupta, Sudhir ^{[6
]}

Fielhauer, Katharina ^{[7
]}

Chavan, Shailesh ^{[8
]}

Yel, Leman ^{[9
]}

机构：

[1] Albert Einstein Coll Med, Bronx, NY 10467 USA

[2] Montefiore Hosp, Bronx, NY USA

[3] Atrium Hlth, Levine Childrens Hosp, Charlotte, NC USA

[4] Washington Univ, Barnes Jewish Hosp, Sch Med, St Louis, MO USA

[5] Allergy Partners North Texas Res, Dallas, TX USA

[6] Univ Calif Irvine, Irvine, CA USA

[7] Baxalta Innovat GmbH, Vienna, Austria

[8] Shire US Inc, Lexington, MA USA

[9] Baxalta US Inc, Cambridge, MA USA

来源：

JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM | 2021年 / 26卷 / 03期

关键词：

facilitated subcutaneous immunoglobulin; real-world data; safety study; chronic inflammatory demyelinating polyradiculoneuropathy;

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：334 / 335

页数：2

共 50 条

[1] LONG-TERM SAFETY OF FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN: INSIGHTS FROM A POSTAUTHORIZATION SAFETY STUDY IN PRIMARY IMMUNODEFICIENCY DISEASES
Rubinstein, Arye
Patel, Niraj
Wedner, H. James
Wasserman, Richard
Gupta, Sudhir
Fielhauer, Katharina
Chavan, Shailesh
Yel, Leman
MUSCLE & NERVE, 2021, 64 : S62 - S62
[2] EUROPEAN POSTAUTHORIZATION SAFETY STUDY ON LONG-TERM HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN IN PRIMARY IMMUNODEFICIENCY DISEASES: INTERIM ANALYSIS
Ellerbroek, Pauline M.
van Paassen, Pieter
Hanitsch, Leif
Plebani, Alessandro
Schmidt, Reinhold E.
van Hagen, P. Martin
Wang, Ping
Fielhauer, Katharina
Leibl, Heinz
Chavan, Shailesh
Yel, Leman
MUSCLE & NERVE, 2020, 62 : S67 - S68
[3] Interim analysis of a postauthorization safety study on long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in primary immunodeficiency disease in Europe
Ellerbroek, P. M.
van Paassen, P.
Hanitsch, L.
Plebani, A.
Schmidt, R. E.
van Hagen, P. M.
Wang, P.
Fielhauer, K.
Leibl, H.
Yel, L.
SWISS MEDICAL WEEKLY, 2019, : 17S - 17S
[4] Interim Analysis of the Global Postauthorization Safety Study of Facilitated Subcutaneous Immunoglobulin Treatment in Patients With Primary Immunodeficiency Diseases
Rubinstein, Arye
Patel, Niraj
Wedner, H. James
Wasserman, Richard L.
Gupta, Sudhir
Fielhauer, Katharina
Chavan, Shailesh
Yel, Leman
JOURNAL OF CLINICAL IMMUNOLOGY, 2020, 40 (SUPPL 1) : S74 - S74
[5] Long-term safety of facilitated subcutaneous immunoglobulin treatment in pregnant women with primary immunodeficiency diseases: results from a registry study
Borte, Michael
Raffac, Stefan
Hrubisko, Martin
Jahnz-Rozyk, Karina
Garcia, Enrique
McCoy, Barbara
Chavan, Shailesh
Nagy, Andras
Yel, Leman
IMMUNOTHERAPY, 2022, 14 (08) : 609 - 616
[6] Long-term Safety of Facilitated Subcutaneous Immunoglobulin Treatment in Patients With Primary Immunodeficiency Diseases: Interim Analysis from a Post-authorization Safety Study
Rubinstein, Arye
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB73 - AB73
[7] Final Analysis of Long-Term Safety of Facilitated Subcutaneous Immunoglobulin Across the Age Range: Results from a Postauthorization Study
Ellerbroek, Pauline
Witte, Torsten
Lougaris, Vassilios
Chen, Jie
Nagy, Andras
Mccoy, Barbara
Yel, Leman
JOURNAL OF CLINICAL IMMUNOLOGY, 2022, 42 (SUPPL 1) : S49 - S50
[8] Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study
Rubinstein, Arye
Mabudian, Mohsen
Mcneil, Donald
Patel, Niraj C.
Wasserman, Richard L.
Gupta, Sudhir
Carrasco, Paz
Chen, Jie
Garcia, Enrique
Nagy, Andras
Yel, Leman
JOURNAL OF CLINICAL IMMUNOLOGY, 2024, 44 (08)
[9] Long-term safety of facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases: final analysis from a post-authorization safety study conducted in the USA
Rubinstein, Arye
Mabudian, Mohsen
McNeil, Donald
Patel, Niraj
Wasserman, Richard
Gupta, Sudhir
Carrasco, Paz
Nagy, Andras
Yel, Leman
CLINICAL IMMUNOLOGY, 2023, 250 : 36 - 37
[10] Interim Analysis of a Post-authorisation Safety Study on the Long-Term Safety of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in Patients with Primary Immunodeficiency Diseases in Europe
Ellerbroek, P. M.
Van Paassen, P.
Hanitsch, L.
Plebani, A.
Schmidt, R. E.
Van Hagen, P. M.
Wang, P.
Fielhauers, K.
Leibls, H.
Chavan, S.
Yel, L.
EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 402 - 403

← 1 2 3 4 5 →